Atria Wealth Solutions’s Matinas BioPharma MTNB Stock Holding History

Atria Wealth Solutions’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-788	Closed	-$14.2K	–	1939
2023 Q2	$14.2K	Hold	788	–	–	﹤0.01%	1851
2023 Q1	$18.5K	Hold	788	–	–	﹤0.01%	1839
2022 Q4	$19.7K	Hold	788	–	–	﹤0.01%	1779
2022 Q3	$25.1K	Hold	788	–	–	﹤0.01%	1723
2022 Q2	$31K	Hold	788	–	–	﹤0.01%	1600
2022 Q1	$32K	Buy	+788	New	+$29K	﹤0.01%	1712

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Atria Wealth Solutions's MTNB Position: Q3 2023 in Review

Atria Wealth Solutions sold out of Matinas BioPharma (MTNB) in Q3 2023, closing a stake of 788 shares — an estimated $14.2K sold.

Atria Wealth Solutions first reported a position in MTNB in Q1 2022 and held it in 6 quarters. The position peaked at $32K in Q1 2022. 47 funds tracked by Wall St. Rank hold MTNB as of Q3 2023.

Atria Wealth Solutions reported no remaining Matinas BioPharma position as of Q3 2023 after selling out during the quarter.
Atria Wealth Solutions sold 788 Matinas BioPharma shares in Q3 2023, an estimated $14.2K.
Atria Wealth Solutions first reported a position in Matinas BioPharma in Q1 2022 and held it in 6 quarters.
Atria Wealth Solutions's Matinas BioPharma position peaked at $32K in Q1 2022.
47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2023.

Based on Atria Wealth Solutions's 13F filing for Q3 2023, filed 8 Nov 2023.